For example, the phase 2 PAMELA clinical trial showed that dual anti-HER2 and endocrine therapies increased the partially conditional rate-based (pCRB) and pCR, especially in HER2+/HR+ BC [228]. The gene discussed is ERBB2; the disease is breast cancer.